This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Karo Pharma Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Dividendenausschüttung

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-kr0.69
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if KARO's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if KARO's dividend payments have been increasing.

Dividendenrendite im Vergleich zum Markt

Karo Pharma Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von KARO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (KARO)	0%
Untere 25 % des Marktes (SE)	1.4%
Markt Top 25 % (SE)	4.2%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (KARO)	n/a

Bemerkenswerte Dividende: Unable to evaluate KARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate KARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: KARO is not paying a notable dividend for the Swedish market.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as KARO has not reported any payouts.

This company listing is no longer active

Karo Pharma Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Is Karo Pharma (STO:KARO) A Risky Investment?

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

New 90-day low: kr48.85

New 90-day low: kr51.10

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: kr58.10

New 90-day low: kr61.10

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen